John Wilson
Directeur/Membre du Conseil chez MARKER THERAPEUTICS, INC.
Fortune : 8 M $ au 30/04/2024
Profil
John R.
Wilson is the founder of Wilson Wolf Manufacturing Corp.
(founded in 1998) and AlloVir, Inc. (founded in 2013).
At Wilson Wolf Manufacturing Corp., he holds the title of Chief Executive Officer starting in 1998.
At AlloVir, Inc., he served as an Independent Non-Executive Director from 2018 to 2022.
Mr. Wilson is also the founder of Marker Cell Therapy, Inc. Mr. Wilson's current job is as an Independent Director at Marker Therapeutics, Inc. (since 2018).
His former job was as a Principal at Cellex Biosciences, Inc. Mr. Wilson's education includes an undergraduate degree from Hamline University and the University of Minnesota.
Détentions connues dans des sociétés publiques
| Société | Date | Nombre d'actions | Valorisation | Date de valorisation |
|---|---|---|---|---|
ALLOVIR INC
4,66% | 31/12/2023 | 5 355 877 ( 4,66% ) | 4 M $ | 30/04/2024 |
| 31/03/2024 | 781 200 ( 8,77% ) | 3 M $ | 30/04/2024 |
Postes actifs de John Wilson
| Sociétés | Poste | Début |
|---|---|---|
| MARKER THERAPEUTICS, INC. | Directeur/Membre du Conseil | 17/10/2018 |
Wilson Wolf Manufacturing Corp.
 Wilson Wolf Manufacturing Corp. Medical SpecialtiesHealth Technology Wilson Wolf Manufacturing Corp. is a private company based in St. Paul, MN that was founded in 1998 by John R. Wilson, who has been the CEO since then. The company specializes in developing and manufacturing innovative cell culture technologies, with a focus on advancing the field of cell and gene therapy through its patented G-Rex® bioreactor technology. The G-Rex® product line has experienced an average annual sales growth rate of 50% over the last 5 years and is commonly used in every phase of cell and gene therapy manufacturing. In 2020, Wilson Wolf formed a joint venture with Bio-Techne and Fresenius-Kabi called ScaleReady to bring more capacity to advance the cell and gene therapy field. The company's patented products and protocols are used for numerous applications, including monoclonal antibody production, corneal transplants, porcine heart valve testing, mesenchymal cell production, and islet transplants for type 1 diabetes. The company's technology represents a paradigm shift in cell culture devices, resulting in a process for cell culture that is less costly and more effective. | Directeur Général | 01/01/1998 |
Anciens postes connus de John Wilson
| Sociétés | Poste | Fin |
|---|---|---|
| ALLOVIR, INC. | Fondateur | 17/05/2022 |
| Cellex Biosciences, Inc. | Corporate Officer/Principal | - |
Marker Cell Therapy, Inc.
 Marker Cell Therapy, Inc. Miscellaneous Commercial ServicesCommercial Services Marker Cell Therapy, Inc. develops clinical stage immuno-oncology therapies. The company is headquartered in New Brighton, MN. | Directeur Général | - |
Formation de John Wilson
| Hamline University | Undergraduate Degree |
| University of Minnesota | Undergraduate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 2 |
|---|---|
| MARKER THERAPEUTICS, INC. | Health Technology |
| ALLOVIR, INC. | Health Technology |
| Entreprise privées | 3 |
|---|---|
| Cellex Biosciences, Inc. | Distribution Services |
Wilson Wolf Manufacturing Corp.
Wilson Wolf Manufacturing Corp. Medical SpecialtiesHealth Technology Wilson Wolf Manufacturing Corp. is a private company based in St. Paul, MN that was founded in 1998 by John R. Wilson, who has been the CEO since then. The company specializes in developing and manufacturing innovative cell culture technologies, with a focus on advancing the field of cell and gene therapy through its patented G-Rex® bioreactor technology. The G-Rex® product line has experienced an average annual sales growth rate of 50% over the last 5 years and is commonly used in every phase of cell and gene therapy manufacturing. In 2020, Wilson Wolf formed a joint venture with Bio-Techne and Fresenius-Kabi called ScaleReady to bring more capacity to advance the cell and gene therapy field. The company's patented products and protocols are used for numerous applications, including monoclonal antibody production, corneal transplants, porcine heart valve testing, mesenchymal cell production, and islet transplants for type 1 diabetes. The company's technology represents a paradigm shift in cell culture devices, resulting in a process for cell culture that is less costly and more effective. | Health Technology |
Marker Cell Therapy, Inc.
Marker Cell Therapy, Inc. Miscellaneous Commercial ServicesCommercial Services Marker Cell Therapy, Inc. develops clinical stage immuno-oncology therapies. The company is headquartered in New Brighton, MN. | Commercial Services |
